Claims
- 1. A compounds of the formula:
- 2. A compound according to claim 1 wherein at least one of R3 and R4 is other than hydrogen, or a pharmaceutically acceptable salt thereof.
- 3. A compound according to claim 2 wherein R1 and R2 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxy and acetoxy, and R3 and R4 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy and amino, or a pharmaceutically acceptable salt thereof.
- 4. A compound according to claim 3 of the formula:
- 5. A compound according to claim 4 wherein R4 is other than hydrogen, or a pharmaceutically acceptable salt thereof.
- 6. A compound according to claim 5 wherein R3 and R4 are other than hydrogen, or a pharmaceutically acceptable salt thereof.
- 7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier at least one compound according to claim 1.
- 8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier at least one compound according to claim 2.
- 9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier at least one compound according to claim 3.
- 10. A method of treating an individual for a cell proliferative disorder comprising administering to said individual an effective amount of at least one compound according to claim 1.
- 11. A method of treating an individual for a cell proliferative disorder comprising administering to said individual an effective amount of at least one compound according to claim 2.
- 12. A method of treating an individual for a cell proliferative disorder comprising administering to said individual an effective amount of at least one compound according to claim 3.
- 13. A method according to claim 10 wherein the cell proliferative disorder is selected from the group consisting of hemangiomatosis in new born, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, ganglioneuromatosis, keloid formation, Pagets Disease of the bone, fibrocystic disease of the breast, Peronies and Duputren's fibrosis, restenosis and cirrhosis.
- 14. A method according to claim 10 wherein the cell proliferative disorder is cancer.
- 15. A method of according to claim 14 wherein the cancer is selected from the group consisting of ovarian, breast, prostate, lung, renal, colorectal and brain cancers, or the cancer is a leukemia.
- 16. A method of inducing apoptosis of tumor cells in an individual afflicted with cancer comprising administering to said individual an effective amount of at least one compound according to claim 1.
- 17. A compound of the formula:
- 18. A compound according to claim 17 wherein at least one of R3 and R4 is other than hydrogen.
- 19. A compound according to claim 18 wherein R1 and R2 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, hydroxy and acetoxy, and R3 and R4 are selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy and amino.
- 20. A compound according to claim 19 of the formula:
CROSS-REFERENCE TO RELATED APPLICATION
[0001] The priority of co-pending U.S. provisional patent application Serial No. 60/271,762, filed Feb. 27, 2001, is claimed. The entire disclosure of the aforesaid provisional patent application is incorporated herein by reference.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US02/05817 |
2/26/2002 |
WO |
|